Naoki Terakawa
Yonago, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results.
Journal: BMC women's health
Published: February 26, 2021
Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.
Journal: Fertility and sterility
Published: March 30, 2020
Epigenetic aberration of gene expression in endometriosis.
Journal: Frontiers in bioscience (Elite edition)
Published: June 11, 2013
Fibroblast growth factor receptor 2 expression may be involved in transformation of ovarian endometrioma to clear cell carcinoma of the ovary.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: May 04, 2013
Clinical characteristics of patients in Japan with ovarian cancer presumably arising from ovarian endometrioma.
Journal: Gynecologic and obstetric investigation
Published: April 15, 2013
Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: June 08, 2012
The role of NF-kappaB in endometriosis.
Journal: Frontiers in bioscience (Scholar edition)
Published: June 02, 2012
Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.
Journal: Human cell
Published: May 15, 2012
Gonadotropin-releasing hormone analogues reduce the proliferation of endometrial stromal cells but not endometriotic cells.
Journal: Gynecologic and obstetric investigation
Published: April 26, 2012
Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2.
Journal: Human cell
Published: April 18, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026